The present invention relates to a compound of formula I, wherein R1 is selected from the group consisting of hydrogen and lower alkyl； each R2 is independently selected from the group consisting of hydrogen and lower alkyl； each R3 is independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, phenyloxy, benzyloxy, halogen and lower alkyl substituted by halogen； R4 is selected from the group consisting of hydrogen and lower alkyl； X is selected from the group consisting of &mdash；CH2&mdash；, &mdash；CH&mdash； and &mdash；O&mdash；； Y is selected from the group consisting of &mdash；CH2&mdash；, &mdash；CH2CH2&mdash；, &mdash；CH&mdash； and a bond； with the proviso that, when X is &mdash；O&mdash；, Y is &mdash；CH2&mdash；； Z is selected from the group consisting of &mdash；CH2&mdash； and &mdash；CH&mdash；； m is 1 or 2； and n is 1 or 2. The invention relates also to a pharmaceutically-acceptable acid-addition salt of such a compound, methods for making the compound, and a composition comprising such a compound. It has been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1.
